Ryan Barbara 4

What Happened

Ryan Barbara, a director of MiNK Therapeutics, sold a total of 1,500 shares of INKT common stock in open-market transactions on March 9–10, 2026, for aggregate proceeds of approximately $22,053. The sales were in four tranches: 200 shares at $10.17, 300 shares at $15.28, 500 shares at $15.57, and 500 shares at $15.30. These were sales (S), not purchases or option exercises.

Key Details

• Transaction dates and prices:
  • 2026-03-09: 200 shares sold at $10.17 — $2,035
  • 2026-03-10: 300 shares sold at $15.28 — $4,585
  • 2026-03-10: 500 shares sold at $15.57 — $7,783
  • 2026-03-10: 500 shares sold at $15.30 — $7,650
• Total shares sold: 1,500; total proceeds ≈ $22,053.
• Shares owned after the transactions: not reported in the provided filing details.
• Footnote: The filing states these shares were the common stock Ms. Barbara received as compensation for board service (i.e., she sold previously granted/compensatory shares).
• Filing timeliness: Form 4 was filed on 2026-03-11 for transactions dated Mar 9–10, 2026; the filing appears timely based on standard Form 4 reporting windows.
• No 10b5-1 plan, option exercises, gifts, or tax-withholding reported in the provided data.

Context

Sales of shares received as director compensation are common and often reflect routine liquidity needs or portfolio management rather than a change in view about the company. This report documents a disposal by a director; it is factual information investors can use alongside other data but does not, by itself, indicate management sentiment.